Skip to Content
Merck
CN
  • Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.

Synthesis and antidiabetic performance of β-amino ketone containing nabumetone moiety.

Bioorganic & medicinal chemistry (2012-03-01)
Hang Wang, Ju-fang Yan, Xiao-li Song, Li Fan, Jin Xu, Guang-ming Zhou, Li Jiang, Da-cheng Yang
ABSTRACT

We wish to report the further design and improved synthesis that resulted in two series of target molecules, TM-1 and TM-2, with remarkably simplified structures containing β-amino ketone of discrete nabumetone moiety. These were obtained via a 'one-pot, two-step, three-component' protocol of Mannich reaction with yield up to 97%. A total of 28 out of 31 new compounds were characterized using (1)H NMR, (13)C NMR, ESI MS and HRMS techniques. Studies on their antidiabetic activities, screened in vitro at 10 μg mL(-1) level, indicate that TM-2 possesses peroxisome proliferator-activated receptor activation and α-glucosidase inhibition activity significantly stronger than that of TM-1, and also that of the series B compounds that were previously synthesized by the group. Analysis of the structure-activity relationship points to the sulfanilamide unit as the most probable potent group of β-amino ketone and, on the basis of which, a tangible strategy is presented for the development of new antidiabetic drugs.

MATERIALS
Product Number
Brand
Product Description

Supelco
Sulfanilamide, VETRANAL®, analytical standard
Sigma-Aldrich
Sulfanilamide, ≥98%
Supelco
Sulfanilamide melting point standard, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Sulfanilamide, puriss. p.a., ≥98% (calc. to the dried substance)
Nabumetone, European Pharmacopoeia (EP) Reference Standard